Aims: To determine the value of a topical carbonic anhydrase inhibitor for extended treatment of cystoid macular edema (CME) in patients with retinitis pigmentosa (RP).
Methods: Eight patients with RP and foveal cystic-appearing lesions observed on fundus examination and by optical coherence tomography (OCT) testing were treated with a topical form of carbonic anhydrase inhibitor.
Results: Foveal cystic-like spaces were documented by OCT testing in all eight patients prior to treatment. All patients showed a significant reduction in their foveal thickness (FT) and foveal zone thickness (FZT) in at least one eye after using 2% dorzolamide three times a day for 1 or 2 months. Six patients demonstrated an improvement in both eyes. After an additional 6 to 13 months of the same treatment regimen, of six patients who showed a sustained reduction in FT and FZT in at least one eye, four demonstrated this reduction in both eyes. While they still remained on Trusopt, a recurrence (rebound) of CME in both eyes was observed in two patients while one patient showed a sustained improvement in one eye and rebound of CME in the other eye. Out of 8 patients, 3 showed an improvement of their visual acuity by 7 letters or more, in at least one eye, on Snellen acuity charts which was determined as clinically significant.
Conclusion: Results from our study suggest that RP patients could potentially sustain a beneficial effect from continued treatment with a topical form of carbonic anhydrase inhibitor.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.